

# MENINGITIS A


# DEADLY

# EXPENSIVE

# PREVENTABLE

## MENINGITIS A

threatens the lives of **450 million people** across 26 countries in Africa's "Meningitis Belt," mostly children and young adults.



## MENINGITIS kills within hours



# THOUSANDS DIE

in years with large outbreaks.



# 1 in 10

die within 2 days even when antibiotics are available.



# 1 in 4

survivors are left with permanent disabilities such as paralysis, blindness, hearing loss, seizures, and intellectual disability.

## MENINGITIS treatment is costly

for both families and nations and contributes to the cycle of poverty.



Each case of meningitis in a family results in a sudden cost of about **\$90**—what is about 3 or 4 months of the family's income.



The permanent disabilities caused by meningitis leave survivors less able to care for themselves and less likely to earn income.

## The MenAfriVac® vaccine



# protects against meningitis A... saving lives and money

# \$0.40

MenAfriVac® became available for use in Africa in 2010 priced at just \$0.40 per dose. Over 217 million people had received the vaccine by the end of 2014.



A prevention cost of **\$0.40 per person** vs. a treatment cost of **\$90 per person**.

# 450 MILLION

The vaccine is targeted to protect 450 million people at risk from meningitis by 2016 and save nearly 150,000 lives.



MenAfriVac® is the first vaccine for use in Africa that can be transported and stored for as long as 4 days without refrigeration or even an ice pack. This saves money and allows for safe delivery to people in even the most remote areas.

**The introduction of this vaccine is a giant step toward achieving elimination of epidemic meningitis as a public health problem in sub-Saharan Africa.**



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention